Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein

Neurobiology of Disease

Volumn 70, Issue , 2014, Pages 204-213

  Subramaniam, Sudhakar Raja ^a   Vergnes, Laurent ^a   Franich, Nicholas R ^a   Reue, Karen ^a   Chesselet, Marie Francoise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alpha synuclein; Lipid peroxidation; Mitochondrial dysfunction; Oxidative damage; Peroxiredoxin

Indexed keywords

ALPHA SYNUCLEIN; MALONALDEHYDE; PEROXIREDOXIN 2; MITOCHONDRIAL DNA; PEROXIREDOXIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SNCA PROTEIN, HUMAN; 4 HYDROXYNENAL; CYTOCHROME C OXIDASE; GENOMIC DNA; LIPID PEROXIDE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SUCCINATE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN CORTEX; BRAIN LEVEL; BRAIN REGION; CELL FUNCTION; CELL LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPID PEROXIDATION; MALE; MESENCEPHALON; MITOCHONDRIAL RESPIRATION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; AGING; ANIMAL; C57BL MOUSE; DBA MOUSE; DOPAMINERGIC NERVE CELL; GENETICS; HUMAN; METABOLISM; MITOCHONDRION; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; ANALYZER; ANIMAL CELL; BRAIN NERVE CELL; ENZYME ACTIVITY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PROTEIN OVEREXPRESSION; TISSUE SPECIFICITY; VENTRAL MIDBRAIN; WILD TYPE;

AGING; ALPHA-SYNUCLEIN; ANIMALS; CEREBRAL CORTEX; CORPUS STRIATUM; DNA, MITOCHONDRIAL; DOPAMINERGIC NEURONS; ELECTRON TRANSPORT COMPLEX I; HUMANS; LIPID PEROXIDATION; MESENCEPHALON; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; MITOCHONDRIA; OXIDATIVE STRESS; PEROXIREDOXINS;

EID: 84904749389     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.06.017     Document Type: Article

References (49)

1. Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004, 4:3943-3952.
2. Bender A., Desplats P., Spencer B., Rockenstein E., Adame A., Elstner M., Laub C., Mueller S., Koob A.O., Mante M., Pham E., Klopstock T., Masliah E. TOM40 mediates mitochondrial dysfunction induced by alpha-synuclein accumulation in Parkinson's disease. PLoS One 2013, 8:e62277.
3. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 1999, 73:1127-1137.
4. Bueler H. Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease. Apoptosis 2010, 15:1336-1353.
5. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., Meredith G.E., Surmeier D.J. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007, 447:1081-1086.
6. Chesselet M.F., Richter F., Zhu C., Magen I., Watson M.B., Subramaniam S.R. A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("line 61") mice. Neurotherapeutics 2012, 9:297-314.
7. Chinta S.J., Andersen J.K. Redox imbalance in Parkinson's disease. Biochim. Biophys. Acta 2008, 1780:1362-1367.
8. Chinta S.J., Mallajosyula J.K., Rane A., Andersen J.K. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 2010, 486:235-239.
9. Cookson M.R., van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp. Neurol. 2008, 209:5-11.
10. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283:9089-9100.
11. Edwards T.L., Scott W.K., Almonte C., Burt A., Powell E.H., Beecham G.W., Wang L., Zuchner S., Konidari I., Wang G., Singer C., Nahab F., Scott B., Stajich J.M., Pericak-Vance M., Haines J., Vance J.M., Martin E.R. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 2010, 74:97-109.
12. Elkon H., Don J., Melamed E., Ziv I., Shirvan A., Offen D. Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. J. Mol. Neurosci. 2002, 18:229-238.
13. Fang J., Nakamura T., Cho D.H., Gu Z., Lipton S.A. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18742-18747.
14. Gautam A.H., Zeevalk G.D. Characterization of reduced and oxidized dopamine and 3,4-dihydrophenylacetic acid, on brain mitochondrial electron transport chain activities. Biochim. Biophys. Acta 2011, 1807:819-828.
15. Gluck M.R., Zeevalk G.D. Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases. J. Neurochem. 2004, 91:788-795.
16. Guardia-Laguarta C., Area-Gomez E., Rub C., Liu Y., Magrane J., Becker D., Voos W., Schon E.A., Przedborski S. Alpha-synuclein is localized to mitochondria-associated ER membranes. J. Neurosci. 2014, 34:249-259.
17. Hattori N., Tanaka M., Ozawa T., Mizuno Y. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann. Neurol. 1991, 30:563-571.
18. Hu X., Weng Z., Chu C.T., Zhang L., Cao G., Gao Y., Signore A., Zhu J., Hastings T., Greenamyre J.T., Chen J. Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J. Neurosci. 2011, 31:247-261.
19. Ichimiya S., Davis J.G., O'Rourke D.M., Katsumata M., Greene M.I. Murine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of the brain most susceptible to hypoxic and ischemic injury. DNA Cell Biol. 1997, 16:311-321.
20. Jin M.H., Lee Y.H., Kim J.M., Sun H.N., Moon E.Y., Shong M.H., Kim S.U., Lee S.H., Lee T.H., Yu D.Y., Lee D.S. Characterization of neural cell types expressing peroxiredoxins in mouse brain. Neurosci. Lett. 2005, 381:252-257.
21. Jones G.M., Vale J.A. Mechanisms of toxicity, clinical features, and management of diquat poisoning: a review. J. Toxicol. Clin. Toxicol. 2000, 38:123-128.
22. Keeney P.M., Xie J., Capaldi R.A., Bennett J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 2006, 26:5256-5264.
23. Lansbury P.T., Lashuel H.A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006, 443:774-779.
24. Li W.W., Yang R., Guo J.C., Ren H.M., Zha X.L., Cheng J.S., Cai D.F. Localization of alpha-synuclein to mitochondria within midbrain of mice. Neuroreport 2007, 18:1543-1546.
25. McCoy M.K., Cookson M.R. Mitochondrial quality control and dynamics in Parkinson's disease. Antioxid. Redox Signal. 2012, 16:869-882.
26. McGuire V., Van Den Eeden S.K., Tanner C.M., Kamel F., Umbach D.M., Marder K., Mayeux R., Ritz B., Ross G.W., Petrovitch H., Topol B., Popat R.A., Costello S., Manthripragada A.D., Southwick A., Myers R.M., Nelson L.M. Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium. J. Neurol. Sci. 2011, 307:22-29.
27. Mollace V., Iannone M., Muscoli C., Palma E., Granato T., Rispoli V., Nistico R., Rotiroti D., Salvemini D. The role of oxidative stress in paraquat-induced neurotoxicity in rats: protection by non peptidyl superoxide dismutase mimetic. Neurosci. Lett. 2003, 335:163-166.
28. Nakamura K., Nemani V.M., Wallender E.K., Kaehlcke K., Ott M., Edwards R.H. Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. J. Neurosci. 2008, 28:12305-12317.
29. Rabinovic A.D., Lewis D.A., Hastings T.G. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 2000, 101:67-76.
30. Ritz B.R., Manthripragada A.D., Costello S., Lincoln S.J., Farrer M.J., Cockburn M., Bronstein J. Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ. Health Perspect. 2009, 117:964-969.
31. Ritz B., Rhodes S.L., Qian L., Schernhammer E., Olsen J.H., Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 2010, 67:600-606.
32. Rockenstein E., Mallory M., Hashimoto M., Song D., Shults C.W., Lang I., Masliah E. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 2002, 68:568-578.
33. Rogers G.W., Brand M.D., Petrosyan S., Ashok D., Elorza A.A., Ferrick D.A., Murphy A.N. High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria. PLoS One 2011, 6:e21746.
34. Ryan S.D., Dolatabadi N., Chan S.F., Zhang X., Akhtar M.W., Parker J., Soldner F., Sunico C.R., Nagar S., Talantova M., Lee B., Lopez K., Nutter A., Shan B., Molokanova E., Zhang Y., Han X., Nakamura T., Masliah E., Yates J.R., Nakanishi N., Andreyev A.Y., Okamoto S.I., Jaenisch R., Ambasudhan R., Lipton S.A. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription. Cell 2013, 155(6):1351-1364.
35. Sarafian T.A., Verity M.A., Vinters H.V., Shih C.C., Shi L., Ji X.D., Dong L., Shau H. Differential expression of peroxiredoxin subtypes in human brain cell types. J. Neurosci. Res. 1999, 56:206-212.
36. Sarafian T.A., Ryan C.M., Souda P., Masliah E., Kar U.K., Vinters H.V., Mathern G.W., Faull K.F., Whitelegge J.P., Watson J.B. Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human alpha-synuclein. PLoS One 2013, 8:e63557.
37. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
38. Shavali S., Brown-Borg H.M., Ebadi M., Porter J. Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci. Lett. 2008, 439:125-128.
39. Siddiqui A., Chinta S.J., Mallajosyula J.K., Rajagopolan S., Hanson I., Rane A., Melov S., Andersen J.K. Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic. Biol. Med. 2012, 53:993-1003.
40. Spillantini M.G., Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N. Y. Acad. Sci. 2000, 920:16-27.
41. Subramaniam S.R., Chesselet M.F. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog. Neurobiol. 2013, 106-107:17-32.
42. Thiruchelvam M., Prokopenko O., Cory-Slechta D.A., Buckley B., Mirochnitchenko O. Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat+maneb-induced Parkinson disease phenotype. J. Biol. Chem. 2005, 280:22530-22539.
43. Uversky V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem. 2007, 103:17-37.
44. Vergnes L., Chin R., Young S.G., Reue K. Heart-type fatty acid-binding protein is essential for efficient brown adipose tissue fatty acid oxidation and cold tolerance. J. Biol. Chem. 2011, 286:380-390.
45. Wang A., Costello S., Cockburn M., Zhang X., Bronstein J., Ritz B. Parkinson's disease risk from ambient exposure to pesticides. Eur. J. Epidemiol. 2011, 26:547-555.
46. Winklhofer K.F., Tatzelt J., Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 2008, 27:336-349.
47. Yumino K., Kawakami I., Tamura M., Hayashi T., Nakamura M. Paraquat- and diquat-induced oxygen radical generation and lipid peroxidation in rat brain microsomes. J. Biochem. 2002, 131:565-570.
48. Zhang L., Zhang C., Zhu Y., Cai Q., Chan P., Ueda K., Yu S., Yang H. Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Res. 2008, 1244:40-52.
49. Zheng B., Liao Z., Locascio J.J., Lesniak K.A., Roderick S.S., Watt M.L., Eklund A.C., Zhang-James Y., Kim P.D., Hauser M.A., Grunblatt E., Moran L.B., Mandel S.A., Riederer P., Miller R.M., Federoff H.J., Wullner U., Papapetropoulos S., Youdim M.B., Cantuti-Castelvetri I., Young A.B., Vance J.M., Davis R.L., Hedreen J.C., Adler C.H., Beach T.G., Graeber M.B., Middleton F.A., Rochet J.C., Scherzer C.R. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2010, 2:52ra73.